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Importance of the field: Migraine and cluster headache are disabling syndromes that often require 
prophylactic treatment. Valproate semisodium ER is FDA-approved for the treatment of epilepsy, 
acute mania in bipolar disorder, and migraine prophylaxis.  
Areas covered in this review: We reviewed literature regarding valproate semisodium ER 
pharmacokinetics and its use in migraine and cluster headache prophylaxis.  
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What the reader will gain: Valproate semisodium ER is well-studied and effective in the 
preventive treatment of migraine and cluster headache. This article reviews the evidence for its 
use, describes how to administer and dose this medication, and reviews important safety 
precautions.  
Take-home message: Valproate semisodium ER is effective in the prophylactic treatment of 
migraine and cluster headache. This once-a-day dosing formulation may increase compliance. 
  
Keywords: Cluster headache, migraine prophylaxis, valproate, valproate semisodium ER 
 
1. Introduction  
1.1 Migraine headache 
Migraine is a common neurologic disorder characterized by multiple usually severe attacks of 
head pain and associated symptoms. A typical migraine attack lasts from four to 72 hours. 
Migraine pain characteristics include pulsating quality, moderate to severe pain, unilateral 
location, and aggravation by or avoidance of physical activity [1]. Associated symptoms that 
accompany headache include photophobia (light sensitivity; 81.9%); phonophobia (sound 
sensitivity; 77.9%), and nausea (60%) [2]. Some migraineurs experience reversible neurologic 
symptoms called aura. Migraine auras usually last between five and 60 minutes and may include 
visual, sensory, or motor symptoms. Patients may experience fully reversible visual symptoms, 
such as flickering lights, spots or lines, or even loss of vision. Some have pins and needles 
sensations, numbness, or fully reversible speech disturbance [3]. Prior to the migraine attack, 
some individuals experience a prodrome, which occurs hours to days before the headache begins. 
Some of the prodrome symptoms are irritability, depression, fatigue, neck stiffness, diarrhea, 
constipation, and food cravings [4]. 
Four to seven percent of men and 15 to 20 percent of women suffer from migraine, with 
the highest migraine prevalence experienced by women between the ages of 25 and 55 [2]. When 
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migraine attacks are severe, patients usually require acute medication for treatment. Non-steroidal 
anti-inflammatory drugs (NSAIDs), triptans, and dihydroergotamine (DHE) are among the acute 
medications commonly used to treat migraine. Migraine prophylaxis, including medications such 
as valproate semisodium ER (VPS ER), is recommended for patients with frequent or particularly 
disabling attacks [5]. Migraine pathophysiology is becoming better understood, and some 
important concepts include cortical spreading depression, the release of inflammatory 
neuropeptides such as calcitonin gene related peptide (CGRP) and substance P, brain 
hyperexcitability, and central sensitization of the trigeminal nucleus caudalis [6-9].  
 
1.2 Cluster headache 
Cluster headache (CH), which can be more disabling than migraine, can also be treated with VPS 
ER. CH prevalence is somewhere between 56 and 401 per 100,000 and, unlike migraine, is more 
common in men [10]. CH attacks are usually located in or around one eye, with at least one 
ipsilateral autonomic feature, such as conjunctival injection, nasal congestion, rhinorrhea, facial 
sweating, and eyelid edema, with miosis or ptosis present. The pain may be described as sharp, 
knife-like, or stabbing. The attacks of excruciating unilateral head pain are intermittent and short-
lived, lasting from 15 to 180 minutes. Unlike migraine patients, patients with CH generally do not 
lie still during attacks and may pace with agitation and restlessness [11, 12]. Acute CH 
medications include triptans, dihydroergotamine (DHE), inhaled oxygen, and intranasal lidocaine 
or capsacin [12-15]. Often CH occurs in cycles lasting weeks to months at a time with prolonged 
remissions. Because CH is occasionally refractory to acute pain medication, or patients may have 
many attacks that require acute treatment, cluster patients usually require preventive medication 
when in cycle to reduce attacks and disability. Common preventive medications include 
verapamil, methysergide, corticosteroids, topiramate, lithium, and forms of valproic acid, such as 
VPS ER. Corticosteroids may be indicated as a faster acting preventive treatment at the start of a 
cycle [16-18]. 
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2. Overview of preventive therapy 
2.1 Reason for preventive therapy 
Although migraine is an episodic disorder, many patients suffer frequent, disabling attacks. 
Preventive therapy, such as VPS ER, may help reduce the frequency, duration, or severity of 
attacks [5] and appears to reduce the risk for developing chronic migraine or medication overuse 
headache [20]. Preventive therapy should be implemented when one of the following headache 
conditions exists: 1) A diagnosis of hemiplegic migraine or migraine that could lead to permanent 
neurologic injury. 2) Migraines that occur more often than once a week, as this may lead to the 
development of chronic migraine or acute medication overuse. 3) Acute medication overuse. 4) 
Patient’s wish to be placed on prophylactic medication. 5) Acute medication causes adverse 
events (AEs) or is not effective. 6) Patient’s life is severely impacted even though he or she is 
using acute medications. Based on these criteria, population-based surveys suggest that migraine 
prophylaxis is underutilized; migraine prophylaxis is indicated for 1 of 3 patients but only 3 to 
13% use them [21-22]. 
 
2.2 Overview of the market for migraine preventive treatment 
Most migraine preventive medications are used off-label, since the medications have usually been 
developed for other indications, such as depression, epilepsy, or hypertension. These preventive 
medications include antiepileptic drugs (AEDs), antidepressants, antihypertensives, and 
botulinum toxin. Many were serendipitously proven to be helpful for migraine prophylaxis. A 
brief overview will be provided in this section; not all medications will be listed and no dosages 
will be given, as this is meant to be a quick synopsis of other preventive medications used.  
AEDs used to treat migraine include carbamazepine, gabapentin, lamotrigine, topiramate, and 
VPS ER. Commonly used antidepressants include tricyclic compounds (amitriptyline, 
nortriptyline, protriptyline) and serotonin-norepinephrine reuptake inhibitors (venlafaxine, 
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duloxetine). Commonly used antihypertensives include many beta blockers (atenolol, metoprolol, 
nadolol, propranolol, timolol), calcium channel blockers (verapamil), and angiotensin-converting 
enzyme inhibitors (lisinopril) [5]. Some natural products, such as riboflavin, butterbur, and 
coenzyme Q10, appear effective for migraine prophylaxis. Due to its safety, magnesium is one 
option for pregnant women who require migraine prophylaxis [23-26]. Nevertheless, some 
preventive medications have been shown to be more efficacious than others in randomized, 
controlled trials. Topiramate, VPS ER, amitriptyline, metoprolol, propranolol, timolol, and 
butterbur are among those with Class I trial proven efficacy. VPS ER, topiramate, propranolol, 
and timolol are the only available FDA-approved medications in the United States for the 
preventive treatment of migraine [27]. Methysergide, an ergot and agonist and antagonist of 
different serotonin receptors, is effective in migraine prophylaxis but has multiple reported AEs, 
including fibrotic disorders, and is no longer available in the United States.  
 
3. Clinical Pharmacology  
3.1 Description 
VPS ER is comprised of sodium valproate and valproic acid in a 1:1 relationship. The chemical 
name is sodium hydrogen bis (2-propylpentanoate). VPS ER dissociates into valproate ion within 
the gastrointestinal tract. It comes in strengths of 125 mg, 250 mg, and 500 mg [28]. VPS ER is 
the international nonproprietary name. Other formulations of VPS ER appear to work in the same 
manner and are generally grouped together as the same medication. The other names of this 
medication will be referred to in this article as there simply are not enough studies on VPS ER 
alone. Other terms include valproate, valproic acid, divalproex sodium, sodium valproate. [29] 
Drug Summary Box 
 
 
Drug name Valproate semisodium, ER 
Phase Launched 
Indications Migraine prophylaxis 
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Pharmacology description Sodium channel antagonist   
GABA receptor agonist  
Voltage-gated sodium channel inhibitor 
Route of administration Alimentary, po 
Chemical structure 
Pivotal trial(s) Table 1, Table 2 
 
 
Pharmaprojects - copyright to Citeline Drug Intelligence (an Informa business). Readers are 
referred to Informa-Pipeline (http://informa-pipeline.citeline.com) and Citeline 
(http://informa.citeline.com).  
 
3.2 Pharmacodynamics/mechanism    
The exact mechanism of action for the therapeutic effect of VPS ER is unclear, but there are 
many possible causes. It inhibits gamma-aminobutyric acid (GABA) transaminase and the 
catabolism of GABA, an inhibitory neurotransmitter. It is also postulated that increased GABA 
concentrations are present from activation of glutamic acid decarboxylase. VPS ER is also a 
sodium channel antagonist, modulates calcium channels, and may suppress N-methyl-D-aspartic 
acid (NMDA) excitatory neurotransmission. It is also postulated that VPS ER stops the 5-HT 
neurons of the dorsal raphe from firing and modulates serotonergic and dopaminergic 
transmission. Preventive medications such as VPS ER have many different mechanisms of action, 
including actions at serotonin and norepinephrine receptors, modulation of sodium and glutamate, 
and inhibition of nitric oxide production. [29-30] VPS ER may suppress cortical spreading 
depression (CSD), a depolarization or excitation of neuronal and glial membranes that move 
across the cortex at a rate of three to five millimeters per minute, which is then followed by a 
wave of inhibition [31]. Supression of CSD could be an important mechanism of action for all 
effective migraine prophylactic medictions. [32]. These mechanisms suggest that VPS ER, like 
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many other migraine preventive drugs, is effective over time due to reduction of cortical 
hyperexcitability. 
  
3.3 Pharmacokinetics  
Average bioavailability of VPS ER given once-daily under both non-fasting and fasting 
conditions was 89% relative to an equal total dose of VPS given two, three, or four times a day.. 
VPS ER is a weak inhibitor of multiple CYP-P450 isozymes. VPS ER is bioequivalent to VPS 
when VPS ER is given in an eight to 20 percent higher dose than VPS [33-34]. 
 
3.4 Metabolism/excretion  
VPS ER undergoes hepatic metabolism via the CYP-P450 system. Mitochondrial beta oxidation 
accounts for over 40% of its metabolism and is the other major metabolic pathway. The mean 
terminal half-life for VPS ER monotherapy ranges from 9 to 16 hours following oral doses of 250 
to 1000 mg. Patients on enzyme-inducing antiepileptic drugs, such as phenytoin, carbamazepine 
and phenobarbital, will clear VPS ER more rapidly, with a half-life of 5-12 hours. Elderly 
patients and those with hepatic dysfunction eliminate VPS ER more slowly. The half-life 
increases to 12 to 18 hours in individuals with significant liver impairment [29]. 
 
3.5 Overall safety and tolerability  
VPS ER use is associated with multiple potential AEs. VPS ER has a similar or somewhat lower 
AE rate compared with other forms of valproate, such as immediate-release forms. In one study, 
the two forms divalproex and divalproex ER had similar AEs [34], but in another divalproex 
study, the extended-release version avoided high peak serum drug levels and is thus postulated to 
have fewer AE’s. The study concluded that individuals on the extended-release form had fewer 
tremors and gastrointestinal complaints and less weight gain [35-36]. The once-daily dosing of 
VPS ER may increase medication compliance and decrease rates of discontinuation [37].  
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In placebo-controlled migraine trials, divalproex sodium users were shown to have more AEs 
compared to patients who were given placebo. Gastrointestinal (GI) symptoms were the most 
commonly reported AEs in migraineurs. GI AEs include nausea (31%), dyspepsia (13%), 
diarrhea (12%), vomiting (11%), and abdominal pain (9%). Asthenia (20%), somnolence (17%), 
dizziness (12%), tremor (9%), weight gain (8%), back pain (8%), hair loss (7%), and increased 
appetite (6%) also were noted [38]. Decreasing the dose or adding propranolol (a beta-blocker 
commonly used to treat essential tremor and migraine) can reduce tremor [39].  
Other common AEs noted in the treatment of epilepsy and mania include diplopia, blurred vision, 
and cognitive problems. Peripheral edema, bronchitis, pharyngitis, and carnitine depletion may 
also occur [40]. Gastrointestinal symptoms usually decrease after six months and may be 
alleviated if VPS ER is taken with food. In rare cases, pancreatitis can occur months to years after 
initiating VPS ER, but it is usually not fatal. Sudden nausea, vomiting, and anorexia may indicate 
hepatotoxicity and requires caution [41]. VPS ER may be a risk factor for the development of 
polycystic ovarian syndrome (obesity, elevated androgen concentrations, anovulation, and 
hirsutism) [42].  
More serious AEs include hepatic toxicity, which may cause nausea, anorexia, or jaundice. 
Hyperammonemia can cause delirium or tremor and may occur even with normal hepatic 
function testing. VPS ER may cause liver enzyme elevation or thrombocytopenia. Most liver 
enzyme elevations are mild and transient. If hepatic transaminase levels are mildly elevated, VPS 
ER can be continued at the same dose or at a slightly lower dose until the values normalize. 
Patients with elevated ammonia levels may have no clinical symptoms and routinely checking 
ammonia levels in patients without clinical symptoms is not recommended. Encephalopathy is a 
rare but severe AE that may occur with or without hepatic dysfunction [43]. Patients should have 
liver function testing and platelet counts obtained prior to starting the medication. During initial 
VPS ER use, patients may be monitored every couple of months, and then twice a year to ensure 
safety. Monitoring valproate levels may be considered. This can be helpful if a patient is not 
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achieving optimal results, as the valproate level could actually be low and VPS ER can be 
increased until the level reaches a therapeutic range. The accepted therapeutic range in epilepsy is 
between 50 and 100 mcg/ml. The therapeutic range for preventing migraine or CH is unknown. 
The recommended time at which valproate levels should be obtained is 24 hours after dosing, as 
this will be the drug trough concentration [30].  
 
3.6 Precautions  
VPS ER is contraindicated for patients with preexisting thrombocytopenia, liver disease, urea 
cycle disorders, or pancreatitis. Hepatotoxicity usually occurs within the first six months of use 
and children under the age of two are at highest risk of developing hepatotoxicity; migraine and 
CH patients are at a relatively low risk. Facial edema, anorexia, and vomiting may occur. 
Hepatotoxicity secondary to treatment with VPS ER may respond to carnitine, a co-factor in the 
mitochondrial beta-oxidation of fatty acids [44]. Pancreatitis is rare but can occur at the start of 
treatment. Typical symptoms include nausea, vomiting, abdominal pain, and anorexia. 
Hyperammonemia may occur with VPS ER, and liver function tests are insensitive as a marker 
for hyperammonemia. If a patient develops lethargy, vomiting, and changes in mental status; 
order an ammonia level. Patients receiving concomitant VPS ER and topiramate therapy need to 
be closely monitored, as this may increase the risk of developing high ammonia levels [45]. 
Suicial thoughts or behavior have also been reported in patients taking AEDs [46] resulting in an 
FDA warning for all of these drugs. The actual risk of AEDs provoking suicide is under debate 
[47]. 
 
3.7 Teratogenicity  
VPS ER is considered a risk category D medication for use in pregnancy [48] and its use by 
pregnant patients with migraine or bipolar disorder is highly discouraged. The offspring of 
women who take VPS ER during pregnancy, especially in the first trimester, have an increased 
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risk of neural tube defects. Babies born to mothers who take VPS ER during pregnancy have a 
one to two percent chance of developing spina bifida. Other congenital anomalies include 
craniofacial defects and cardiovascular malformations. Pregnant women on VPS ER should be 
considered high risk and these women should take folate. Folic acid is recommended to treat 
women on AEDs at preconception and during the first two to three months of pregnancy 
to help protect against neural tube defects. Four to five mg of folic acid per day is 
recommended prior to a planned pregnancy. Folic acid is protective against neural tube 
defects, but not other anomalies [49]. The risk of developing congenital malformations 
appears higher with valproate as compared to newer AEDs. A systematic literature 
review evaluated pregnant women with epilepsy and the effect of AEDs on the fetus. 
Fetuses born to women taking valproate were the most likely to have malformations 
(10.73% of births), such as craniofacial, or digital abnormalities, cardiac disorders, and 
limb defects, when compared to other AEDs including phenytoin (7.36%), phenobarbital 
(4.91%), carbamazepine (4.62%), and lamotrigine (2.91%) [50]. Valproate may also have 
a,negative effect on later language and behavioral development [51]. VPS ER is secreted in 
breast milk, but at a lower concentration than most other antiepileptic medications [52]. Women 
with migraine generally should avoid VPS ER when they are nursing. 
 
3.8 Drug interactions/contraindications 
VPS ER is a weak inhibitor of the hepatic CYP450 system and causes interactions by displacing 
other medications from plasma proteins and inhibiting hepatic metabolism. VPS ER increases 
plasma levels of many AEDs, such as carbamazepine, lamotrigine, phenobarbital and 
ethosuximide [53]. VPS ER may increase free levels of phenytoin, which can cause toxicity even 
if total serum levels are in the normal therapeutic range. It can also increase levels of warfarin, 
amitriptyline, nortriptyline, zidovudine, valium, cimetidine, chlorpromazine, erythromycin, and 
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nimodipine, among other medications. An individual who received a 50 mg dosage of 
amitriptyline/nortiptyline while taking valproate 500 mg bid had a twenty-one percent decrease in 
plasma clearance of amitriptyline and a thirty-four percent decreased clearance of nortriptyline. 
Amitriptyline levels must be monitored to make sure that they are not high. The tricyclic 
antidepressant dosage should be lowered when using valproate in combination with tricyclic 
antidepressants. Valproate increases the risk of serious rash, such as Stevens Johnson’s syndrome, 
when used concurrently with lamotrigine VPS ER may increase the effects of CNS depressants, 
such as barbiturates and benzodiazepines. Valproate displaces diazepam from its plasma albumin 
binding sites and inhibits its metabolism. The free fraction of diazepam is increased and diazepam 
plasma clearance and volume of distribution is reduced as a result [54]. Patients should not 
operate machinery or drive vehicles until they are aware of how they will react to the medication 
Multiple medications affect the metabolism and clearance of VPS ER. Erythromycin, felbamate, 
and chlorpromazine can increase VPS ER levels and toxicity and salicylates increase the amount 
of free VPS ER [55]. CYP450 inducers, such as phenytoin, phenobarbital, primidone, 
cholestyramine, rifampin, and carbamazepine, may lower VPS ER levels—even doubling the 
clearance of valproate. This means that patients on monotherapy will tend to have longer half-
lives and higher concentrations of the drug than patients receiving polytherapy with some 
antiepileptic drugs. A lower VPS ER level due to the use of enzyme inducers can lead to 
treatment failure. Hyperammonemia and encephalopathy are more common with the concomitant 
use of topiramate and VPS ER. [45]. 
 
4 Clinical efficacy of VPS ER in headache disorders 
4.1 Efficacy of VPS ER in migraine prophylaxis   
Several studies prove the efficacy of VPS ER and its similar formulations as a prophylactic 
treatment for migraine. One multicenter, randomized, double-blind, placebo-controlled, parallel-
group clinical trial found VPS ER to be effective in the prophylactic treatment of migraine 
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headache. Patients were started on a dose of 500 mg once daily for one week, and then the dose 
was increased to 1000 mg once daily, with an option to scale it back to 500 mg during the second 
week if the patient experienced AEs. The mean reduction was 1.2 attacks during a four-week 
period from a baseline mean of 4.4 in the VPS ER group, compared with 0.6 fewer attacks from 
the baseline mean of 4.2 in the placebo group [56]. In another study, the efficacy of sodium 
valproate for migraine was evaluated in a double-blind, randomized, crossover study. The 
individuals were placed on 400 mg of sodium valproate twice per day and 86.2 percent of 29 
patients had a reduction in the frequency or severity of attacks. The mean number of attacks was 
reduced from 15.6 to 8.8. [57]. In another study, 44% of 132 subjects taking divalproex sodium 
had a 50% or greater reduction in migraine frequency, compared with 21% of the placebo group 
[58]. A study of slow-release sodium valproate with 43 patients who had migraine without aura 
using a triple-blind, placebo- and dose-controlled, crossover study revealed 65% of the treatment 
group had a reduction in migraine frequency, compared with 18% for placebo [59]. Matthew and 
Silberstein, in a randomized, placebo-controlled study of divalproex sodium, 500-1500 mg/day, 
demonstrated 48% rate of response (50% or greater reduction in attack frequency) compared with 
14% of placebo group [60]. Apostol et al did not, however, find that VPS ER was effective in 
adolescents with migraine compared with placebo, although 75% reported improvement with few 
AEs [61-2] [Table 1].  
Migraine treatment is usually effective within a couple of weeks, but it may take as long as three 
months for it to become fully effective. If VPS ER is not helpful with migraines, one might 
consider ordering a drug level to make sure that the patient has full benefit of the drug and to 
monitor compliance. Conversely, if a patient has minimal headaches after six months of being 
treated with VPS ER, one may consider tapering or reducing the dose. It should also be stopped if 
the patient is considering pregnancy.  
 
4.2 Efficacy of VPS ER in cluster headache prophylaxis    
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While prophylaxis of CH is not an FDA-approved indication, VPS ER appears to be effective in 
the preventive treatment of CH. There are currently no approved FDA-approved medications for 
CH prophylaxis. The evidence for the use of VPS ER in the prevention of CH is weaker than in 
migraine. In an initial open clinical trial, 73% reported improvement using doses ranging from 
600 mg to 2000 mg/day [63]. Large retrospective studies comfirm these results [64]. But a 
double-blind, placebo-controlled study using sodium valproate 1000-2000 mg/day for CH 
showed a non-significant difference in the two groups, possibily due to improvement in the 
placebo group (62% of the placebo group improved) [65] [Table 2]. It has been suggested that  
CH patients with migrainous features may be good candidates for VPS ER [66]. Intravenous 
valproic acid may be effective in refractory CH [67]. 
 
5. Expert opinion 
VPS ER is an effective medication for migraine and CH prophylaxis, as it is one of only a few 
drugs the FDA has approved for migraine and with multiple studies that demonstrate its 
effectiveness. It also appears effective for some patients with CH, but without good evidence 
from placebo-controlled trials. In addition to these two headache conditions, it may also be used 
with some efficacy in trigeminal neuralgia [68]. VPS ER is also effective for bipolar disorder and 
epilepsy—common co-morbid conditions in migraine patients. The once-daily VPS ER may have 
less sedation and be more likely to improve compliance. Serum levels are reliable and can help 
guide optimal dosing. Unlike phenytoin, a class 1b antiarrhythmic agent, there are no cardiac 
risks. Unlike many migraine preventives, VPS ER is safe in the setting of affective disorders and 
does not affect blood pressure or heart rate. Migraine prophylactic treatment can improve quality 
of life and reduce disability. If patients do not improve with VPS ER, consider ordering a drug 
level to monitor compliance and make sure that the patient has full benefit of the drug. VPS ER 
appears to be among the most effective migraine and CH prophylactic treatments. Intravenous 
valproic acid may even be helpful in the acute treatment of migraine and cluster attacks [69-70]. 
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The use of VPS ER is limited, however, by bothersome and common AEs. These include GI 
distress, weight gain, tremor, alopecia, polycystic ovary syndrome, and, rarely, life-threatening 
conditions, such as liver failure or pancreatitis. Unfortunately, these AEs are often unpredictable 
and due to idiosyncratic reactions. Although some abnormalities (transient liver enzyme 
elevations) are mild, many other migraine and CH medications are available that do not require 
monitoring. In addition, VPS ER has multiple significant drug interactions. One limiting factor is 
that many patients do not improve with preventive treatment with one medication and other 
conditions such as medication overuse or affective disorders. Another limiting factor is that VPS 
ER is not approved for migraine in some countries and is not approved in any country for CH.  
Why does VPS ER seem to be helpful only to some individuals with a diagnosis of migraine or 
CH? The development of serious AEs, such as pancreatitis or liver problems, is unpredictable and 
there is no way to predict the outcome of an individual’s response. The future will hopefully 
bring genetic and immunologic biomarkers to help predict treatment response and identify those 
at risk for serious AEs.. The ultimate goal should be to develop preventive medication treatment 
that would decrease an individual’s disability and headache severity while improving quality of 
life.  
Advances in our understanding of the mechanisms or causes of migraine or CH will also lead to 
better treatment. Hopefully the future will bring new biomarkers, such as genetic markers, 
measures of brain hyperactivity, or levels of neurotransmitters, for headache disorders. The 
precise mechanism of how VPS ER works either for headache or epilepsy is unclear. In the 
upcoming years, it is hoped that diagnosing migraine and CH will be improved. Identifying the 
patients who require preventive treatment would also be a step in the right direction. It is 
important to note that migraine is not just a pain disorder, but rather a multimodal system that 
affects thinking, balance, and a person’s sense of wellbeing.  
 
Conclusion: 
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VPS ER is effective and well-tolerated in the preventive treatment of migraine and potentially 
helpful for many patients with CH. Clinicians should be familiar with the pharmacokinetic 
properties of VPS ER and be aware of potential AEs and required monitoring. 
 
 
 
 
 
 
Table 1: Clinical trials of valproate formulations in migraine prophylaxis 
                   
Trial Author 
Date, 
Reference 
Type of Trial Efficacy Dosage Number 
of 
Patients 
Reference 
Medication 
Freitag, 
Collins; 
2002;[53] 
Randomized, 
double-blind, 
placebo-
controlled, 
parallel-group 
Mean reduction 
in 4-week 
migraine 
headache rate; 
reduction in the 
baseline mean 
from 4.4 to 1.2 
500mg once 
daily for one 
week; dose 
then 
increased to 
1000mg/day 
237 Divalproex 
sodium 
extended-
release 
Hering, 
Kuritzky; 1992 
[54] 
Double blind, 
randomized, 
crossover  
86.2% subjects 
with reduced 
attack frequency, 
severity, or 
duration 
400mg twice 
per day 
29 Sodium 
valproate 
Jensen, Brinck, 
Olesen; 1994 
[55] 
Triple-blind 
placebo and 
dose-
controlled, 
crossover study 
50% reduction in 
migraine 
frequency 
Dose not 
specified 
43 Slow-release 
sodium 
valproate 
Mathew, 
Saper, 
Silberstein; 
1995 [57] 
Randomized 
placebo-
controlled 
43% of the 
subjects with > 
50% reduction in 
migraine 
frequency 
500 to 
1500mg/day  
117 Divalproex 
sodium 
extended-
release 
Apostol, 
Lewis, 
Laforet; 2008 
[58-59] 
Phase 3, Open-
label, 
multicenter 
study of 
adolescents 
75% decrease in 
headache days 
but not superior 
to placebo 
Initial dose 
500mg/day, 
then after 15 
days 
increased to 
1000mg/day 
241 Divalproex 
sodium 
extended-
release 
Freitag, 
Diamond; 
Retrospective 
chart review 
65% had 
improvement in 
Does not 
specify the 
138 
patients 
Divalproex 
sodium 
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2001 [32] with data 
extraction 
migraine  dosage 
 
 
 
Table 2: Clinical trials of valproate formulations in cluster headache prophylaxis  
 
Trial Author Type of Trial Efficacy Dosage Number 
of 
Patients 
Reference 
Medication 
Hering, 
Kuritzky; 
1989 [60] 
Open clinical 
trial 
73% reported 
improvement 
600mg to 
2000mg/day in 
two divided 
doses 
15 Sodium 
valproate 
Gallagher, 
Mueller, 
Freitag; 2002 
[61] 
Retrospective 
multicenter 
study 
73% 
improvement in 
pain 
Dosage not 
specified 
284 Divalproex 
sodium 
El Amrani; 
2002 [62] 
Double-blind 
placebo 
controlled 
No improvement 
when compared 
to placebo 
1,000 to 
2,000mg/day 
96 Sodium 
valproate 
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